The research provides new insights into how the brain creates and stores long-term memories.

Published Date: 08 Mar 2023

To better understand how the brain creates and stores long-term memories, an international team of scientists studied brain circuitry. Their work sheds new light on the functioning of brain circuits.

Read Full News

Latest News

Single IV Ketamine Promising for Depression in MCI

Ketamine is well-tolerated in older adults with both mild cognitive impairment and depression and associated with improved depression scores, a new study shows.

Late Complications Common After CVT, Even After Recovery

Although a majority of patients with cerebral venous sinus thrombosis achieve independence, 1 in 3 may develop delayed complications such as seizures, a study shows.

Activity Trackers May Predict MS Progression

Reduced daytime physical activity, as measured with wearable trackers, is tied to increased risk for multiple sclerosis progression and brain atrophy, new research shows.

WHO Warns Of Health Risks From 'Black Rain' in Iran

The World Health Organization warned on Tuesday that the 'black rain' and toxic compounds in the air in Iran after strikes on ⁠oil facilities could cause respiratory problems.

Wildfire Smoke Tied to Higher Stroke Risk, Greater Severity

Short-term surges in air pollution from wildfire smoke have been linked to a greater incidence and severity of stroke.

Therapeutic Research in Alzheimer’s Disease: What Is New?

Long-term extension trial results with donanemab suggest a widening separation in cognitive decline through 36 months in early Alzheimer’s disease.

Todays Updates

Chemoimmunotherapy Boosts Head and Neck Cancer Response

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

Todays Updates

Chemoimmunotherapy Boosts Head and Neck Cancer Response

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

Latest News

Ketamine is well-tolerated in older adults with both mild cognitive impairment and depression and associated with improved depression scores, a new study shows.

Although a majority of patients with cerebral venous sinus thrombosis achieve independence, 1 in 3 may develop delayed complications such as seizures, a study shows.

Reduced daytime physical activity, as measured with wearable trackers, is tied to increased risk for multiple sclerosis progression and brain atrophy, new research shows.

The World Health Organization warned on Tuesday that the 'black rain' and toxic compounds in the air in Iran after strikes on ⁠oil facilities could cause respiratory problems.

Short-term surges in air pollution from wildfire smoke have been linked to a greater incidence and severity of stroke.

Long-term extension trial results with donanemab suggest a widening separation in cognitive decline through 36 months in early Alzheimer’s disease.

News All Time

Trials Offer Mixed Results on BTK Potential for PPMS

Promising findings for fenebrutinib and disappointing results for tolebrutinib offer mixed results on the potential of BTK inhibitors for primary progressive MS.

Redefining Cognitive Assessment With One Blood Test

Blood p-tau217 testing in real-world practice enhances diagnostic accuracy and neurologists' diagnostic confidence, with the greatest diagnostic shifts seen in mild cognitive impairment and dementia.

What If We’ve Been Wrong About How ADHD Drugs Work?

A new analysis of brain scans from nearly 12,000 children could change the way clinicians and researchers think about how stimulants for ADHD work.

Wrist-Worn Sleep Trackers Predict Depression Relapse

Actigraphy data show irregular sleep-wake rhythms nearly double the risk for relapse in individuals with remitted major depressive disorder.

Vertebral Fractures Tied to Lower Lung Volumes in ILD

Thoracic vertebral fractures may worsen lung function and reduce lung volumes in patients with interstitial lung disease.

Japan Endorses IPS-derived Treatment for Parkinson's

A panel of specialists has endorsed an iPS cell-derived treatment for Parkinson's ⁠disease, paving the ‌way for the world's first medical products based on the technology.

Cognitive Training May Lower Dementia Risk 20 Years Later

In a long-running RCT, older adults who completed adaptive speed-of-processing training with boosters were less likely to develop dementia — a benefit not seen with memory or reasoning training.

FDA Okays Pitolisant for Cataplexy in Pediatric Narcolepsy

With this new indication, pitolisant is now approved to treat excessive daytime sleepiness, cataplexy, or both, in patients aged 6 years or older with narcolepsy.

Lifelong Cognitive Enrichment Tied to Lower Dementia Risk

Lifelong cognitive enrichment is linked to a lower risk for Alzheimer's disease, delayed onset, and better cognitive function despite brain pathology.

NeuroVoices: Katrina Bawden, MSN, MSCN, FNP-C, on Emerging Therapies and Women’s Health Priorities in Multiple Sclerosis Katrina Bawden, MSN, MSCN, FNP-C

A nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.

FDA Accepts New Drug Application for Orexin Agonist Oveporexton in Narcolepsy Type 1, Grants Priority Review Isabella Ciccone, MPH

The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.

NeurologyLive® Brain Games: February 8, 2026 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on diagnosing parasomnias!

Remelyinating Drug Bazedoxifene Fails to Meet End Points in Phase 2 Study of Multiple Sclerosis Louie Pasculli

Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.

Interpreting the DAWN Trial: Where Anti-CD38 Therapy May Fit in NMOSD Care Marco Meglio

Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

ISC 2026 Stroke Updates: Extended Time Windows and Secondary Prevention Strategies Ava L. Liberman, MD, Isabella Ciccone, MPH

Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

American College of Physicians Policy Paper Recommends Retiring 'Provider' Term for Physicians Isabella Ciccone, MPH

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.